Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Mebendazole”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed1978

A comparative study of the effect of oxantel-pyrantel suspension and mebendazole in mixed infections with Ascaris and Trichuris.

A comparative trial was carried out in 4 orphanges in Seoul, to compare the anthelminthic efficacy of oxantel-pyrantel suspension and mebendazole tablets against mixed infections of Ascaris lumbricoides and Trichuris trichiura. 40 patients were divided into 4 groups and received oxantel-pyrantel suspension at 15 or 20mg/kg once only or on 2 consecutive days. Another group of 20 patients was treated with 100mg of mebendazole twice a day for 3 days. Both drugs achieved a 100% cure rate for Ascaris infections. Against Trichuris infections, the average cure rate and egg reduction rate of oxantel-pyrantel treated groups was 87.5% and 92.3% respectively, and that for mebendazole was 65% and 89.1%. There were no side-effects. The results of the present study suggest that oxantel-pyrantel is more effective in the treatment of mixed infections of Ascaris and Trichuris, and was more acceptable to the patients, than mebendazole.

Ascariasis↗
PubMed1991

Investigations on the biotransformation of mebendazole using an isolated perfused rat gut system.

1. The intestinal metabolism of the benzimidazole, mebendazole (MEB), has been investigated using isolated perfused jejunal segments of rats. Significant absorption and intestinal metabolism of the substance was observed. 2. The metabolites, the reduced alpha-hydroxy-analogue, its glucuronide, and the decarbamoylated 2-amino-analogue, were transported into the resorbate collected at the serosal side or were resecreted into the gut lumen. 3. The intestinal decarbamoylation of mebendazole increased up to 20-fold after pretreatment with 3-methylcholanthrene (MC), and complete re-secretion of this metabolite into the gut lumen led to a total loss of the absorption of mebendazole and metabolites across the gut wall. 4. The results indicate the ability of the gut to metabolize mebendazole by phase I and II reactions. 5. An almost complete loss of bioavailability after induction of the gut enzyme system by MC was observed.

Animals↗
PubMed1976

Chemotherapy of hydatid disease (Echinococcus granulosus) in mice with mebendazole and bithionol.

We treated female Swiss Webster mice with heavy, long standing infections of Echinococcus granulosus with mebendazole, 50 mg/kg body weight daily for 10 days and bithionol, 70 mg/kg every other day for four doses. Necropsy performed 6 weeks after completion of therapy showed no gross or histologic differences between untreated controls and bithionol-treated mice or their cysts. Mebendazole-treated mice had a significant decrease in the total number of cysts (15 vs. 100), with many of those present being ruptured. Electron microscopy of intact, mebendazole-treated cysts revealed a marked increase in vacuolization and disarray of the distal cytoplasm, dilated and degenerating microtubules, increase in the size and number of lysosomes, a decrease in the number of normal appearing golgi, and increased density of mitochondria. Several mice died shortly after the termination of mebendazole therapy, all with ruptured cysts. Due to the large volume of the cysts, the presumed cause of death was acute volume overload, but toxic or anaphylactic reactions could not be excluded. We suggest that any proposed chemotherapy of humans with hydatid disease be done cautiously, with careful monitoring.

Animals↗
PubMed1983

Mebendazole treatment of Echinococcus granulosus infection. Report of a case.

A patient with an Echinococcus granulosus cyst of the liver was treated with mebendazole for 94 days before operation. The serum levels of mebendazole varied from 39.4-274 ng/ml. After operation, cyst materials were inoculated into mice which developed hydatid cysts 10 months later. Intestinal absorption of mebendazole is poor and variable, and determination of serum concentrations is necessary during treatment. No apparently successful cases of drug treatment of E. granulosus infection have been verified by animal inoculation of cyst material; therefore, surgery must still be considered the treatment of choice. It is recommended that mebendazole be given prophylactically to prevent spread of the disease at operation.

Adult↗
PubMed1985

Effect of plasma mebendazole concentrations in the treatment of human echinococcosis.

High oral doses of mebendazole were given for a mean period of 23 months to 22 patients with inoperable alveolar or cystic echinococcosis (Echinococcus multilocularis n = 18, E. granulosus n = 4). Clinical, morphological, biochemical and serological findings and plasma mebendazole levels were monitored. Clinical and biochemical improvement or stabilization was observed in 17 patients but the parasitic lesions did not decrease in size in most instances. One patient died shortly after onset of therapy with hemorrhage of esophageal varices. Three patients with alveolar and one with cystic echinococcosis had evidence of progressive disease such as increase of cholestasis, destruction of lumbar vertebrae and growth of an intraperitoneal cyst. The plasma mebendazole levels (4 hr after the morning dose) of the latter 4 patients were 0.09 +/- SD 0.02 mumol/l, while in those with clinical stabilization or improvement it was 0.30 +/- SD 0.14 mumol/l (P less than 0.001). These preliminary data indicate 1) a good clinical response to chemotherapy in most patients despite unchanged size of the parasitic lesions, and 2) a direct correlation of clinical response with plasma mebendazole levels.

Adult↗
PubMed1990

Recurrence rate after discontinuation of long-term mebendazole therapy in alveolar echinococcosis (preliminary results).

The recurrence rate was investigated in 19 patients with non-resectable alveolar echinococcosis after discontinuation of a long-term therapy with mebendazole (average treatment 4.3 years). A control group consisted of 14 patients who underwent radical surgery and finished a course of prophylactic postoperative mebendazole treatment of 2 years. In the controls, no recurrence was observed after a post-therapy period averaging 3.5 years. In contrast, recurrence occurred in 7/19 patients (37%) with non-resectable alveolar echinococcosis an average of 1.6 years after discontinuation of the long-term mebendazole therapy. The absence of clinically detectable recurrence in the remaining 12 patients seems to be due either to spontaneous inactivation of alveolar echinococcosis preceding chemotherapy or too short post-therapy surveillance. The patients with recurrence responded favorably to reintroduction of chemotherapy. The data indicate that mebendazole therapy is parasitostatic rather than parasiticidal.

Adult↗
PubMed1997

Failure of mebendazole in treatment of human hookworm infections in the southern region of Mali.

Preliminary studies indicated that single-dose (500 mg) mebendazole gave disappointing results in the treatment of hookworm infections (Necator americanus) in Mali. A placebo-controlled, randomized trial conducted with the participation of 103 infected subjects (background hookworm prevalence > 50%) confirmed that mebendazole (Vermox) did not reduce parasite burdens significantly, as assessed through fecal egg counts. In contrast, a group of subjects treated with pyrantel (Combantrin) experienced a significant reduction in fecal worm egg counts (overall, both sexes combined showed a 75% reduction). Male subjects carried significantly more intense infections compared with females, but there was no gender difference in response to treatment. A standard egg hatch assay showed that N. americanus from our subjects in Mali was more resistant to benzimidazoles compared with a laboratory-maintained strain that had not been exposed to anthelmintics in more than 100 generations (50% effective dose = 0.12 and 0.07 microg/ml of thiabendazole, respectively), suggesting that, among other possibilities, the development of resistance to the benzimidazoles by N. americanus may have contributed to the drug failure. Whatever the underlying explanation, our results indicate that single-dose treatment with mebendazole is an ineffective treatment for hookworm infections and despite its relatively cheap cost and wide availability, mebendazole should not be considered a drug of choice in the mass treatment of hookworm infections in this region of Mali.

Adolescent↗
PubMed2004

Comparative efficacy of albendazole and three brands of mebendazole in the treatment of ascariasis and trichuriasis.

OBJECTIVE: To evaluate the comparative efficacy of 400 mg albendazole (Smith Kline Beecham) as a single dose and three brands of mebendazole (Janssen, Unibios and East African Pharmaceuticals) at doses of 100 mg twice a day for three consecutive days in the treatment of single or mixed infections with Ascaris lumbricoides and or Trichuris trichiura in four treatment groups of school children. DESIGN: Randomized trial. SETTING: Wondo-Genet, southern Ethiopia. SUBJECTS: School children, aged six to nineteen years. RESULTS: The percentage cure rate and egg reduction rate obtained with albendazole and mebendazole from the three brands were not significantly different in the treatment of ascariasis. However, significant differences were found among the percentage cure rates and egg reduction rates of the four treatment groups in the treatment of trichuriasis. Comparatively, high cure rate (89.8%) and egg reduction rate (99.1%) were observed in vermox (Janssen) treated group followed by Unibios (India) treated group (53.3% and 96.53% cure and egg reduction rates, respectively), whereas low cure rate (17.1%) and egg reduction rate (69.8%) were seen in the albendazole treated group. CONCLUSION: The results of this study suggest that in areas of single or mixed infections with Trichuris trichiura and/or Ascaris lumbricoides are common public health problems and where laboratory facilities are not available to make parasite identification, mebendazole (particularly vermox, a product of Janssen laboratory) would be the drug of choice to treat trichuriasis and ascariasis. However, either mebendazole from the different brands or albendazole is effective in the treatment of ascariasis in areas where trichuriasis is not prevalent.

Adolescent↗
PubMed1976

The effects of mebendazole and fenbendazole on Trichinella spiralis in mice.

Oral administration of either Mebendazole or Fenbendazole at 50 mg/kg body weight was effective in killing a 7-hr Trichinella spiralis infection in mice. Adult worms, 72 hr postingection, were unaffected by the same dose of Fenbendazole, while Mebendazole showed partial activity. Both Mebendazole and Fenbendazole were active against developing muscle larvae. Mebendazole was effective against encysted muscle larvae while 50 mg of Fenbendazole per kg per day for 7 days from 28 days postinfection failed to have any effect on this stage of the life-cycle.

Animals↗
PubMed1976

Mebendazole and pyrantel pamoate as broad-spectrum anthelmintics.

The efficacy of mebendazole and pyrantel pamoate was studied in two groups of 59 and 58 cases, respectively, of patients with polyparasitosis. Mebendazole had a cure rate of 96%, 82.2%, 71.4% and 66.6% in A. lumbricoides, hookworm, T. trichiura and S. stercoralis, respectively, while the corresponding figures for pyrantel pamoate were 92.6%, 85.7%, 19.4% and 0%. Pyrantel pamoate is considered to have no significant effect on T. trichiura and S. stercoralis. None of the drugs had any effect on T. saginata. Both drugs have been found to be equally effective against enterobiasis by various authors. It is recommended that pyrantel pamoate be the drug of choice in cases of multiple parasitic infections excluding T. trichiura and S. stercoralis whereas those with one or both of these in addition to others should be treated with mebendazole. Mebendazole can be prescribed for patients with clinical evidence of helminthic infections even where stool examination is not possible as it covers almost the whole range of common helminthic infections. The only limitation for poorer patients however is its cost. Pyrantel pamoate has a wider applicability for the poorer patients in spite of the fact that it is ineffective against trichurids and S. stercoralis.

Adolescent↗
PubMed2002

Efficacy of alebendazole and mebendazole in the treatment of Ascaris and Trichuris infections.

This study was conducted to evaluate the efficacy of 100 mg mebendazole administered twice a day for three consecutive days and a single dose of 400 mg albendazole for the treatment of single or mixed Ascaris lumbricoides and Trichuris trichiura infections. Both drugs were found to be highly effective against Ascaris lumbricoides infection, with cure rate of over 96% and egg reduction of over 99.8%. However, the efficacy of the two drugs against Trichuris trichiura infection was low. Mebendazole appeared to be more effective against Trichuris trichiura in that it exhibited a cure rate of 34.7% and egg reduction of 92.3% as opposed to albendazole, which exhibited a cure rate and egg reduction rate of 13.9% and 63.4%, respectively. The two drugs appeared to have little effect on Schistosoma mansoni infection. More complaints were reported by individuals treated with albendazole than with mebendazole. In conclusion, mebendazole appears to be safer and more effective for the treatment of single or mixed infections with Trichuris trichiura and Ascaris lumbricoides as compared to albendazole.

Adolescent↗
PubMedDate not supplied

[Double blind study of the efficacy of mebendazole in minor forms of human toxocariasis].

The authors discuss the results of a double-blind, placebo-controlled, randomised study on the efficacy of mebendazole versus placebo in the treatment of human toxocariasis in 45 and 43 patients respectively, who exhibited evocative clinical and biological symptoms and a seropositivity. Scores were used to quantify clinical (20 parameters) and biological (blood count, sedimentation rate, determination of total and anti-Toxocara IgE, serodiagnosis by immunoelectrophoresis) abnormalities. The reassessment were done 1 month after the end of treatment. Analyzing the results showed a similar efficacy of mebendazole and placebo on the score of clinical signs; the score of biological abnormalities was significantly reduced in mebendazole group, but the serodiagnosis by immunoelectrophoresis was the only parameter that was significantly normalized. These results corroborate previous prospective studies and allow to make a conclusion in favour of a moderate efficacy of mebendazole.

Adult↗
PubMed1991

[Mebendazole in the therapy of hydatidosis].

The effectiveness of mebendazole as adjuvant treatment in hydatidosis was evaluated in 19 patients; 12 were treated both before and after surgery, 6 were not treated, one had primary treatment only, owing to the refuse of surgery. Mebendazole was administrated at the dosage of 30-50 mg/kg/day po for 30 days followed by a washout of 15 days, for a mean of 4 cycles (range 1-7) and 12 cycles (range 1-24) before and after surgery, respectively. Patients were monitored by total IgE, specific anti-echinococcus IgE and IgG, at diagnosis, just before surgery and thereafter every six months. Antibody titer decrease was observed soon after the first cycles of medical treatment before surgery, as well as a clear-cut drop after surgery, followed by a continuing decrease after the following cycles of mebendazole. Relapse of disease was observed in two patients only at one and two years after surgery respectively. These preliminary results seem to point out that mebendazole might play a role in the treatment of hydatidosis as adjuvant of surgical therapy.

Adolescent↗
PubMed1987

Comparative study of different doses of mebendazole in hookworm infection.

Sixty six children (40 males, 26 females) aged from 4 to 14 years with hookworm infection were treated with mebendazole. Thirty one and 35 children were treated with mebendazole 300 mg single dose and 600 mg conventional regimen respectively. Stool examination by Kato-Katz technique were done for 3 consecutive days before treatment and on day 14-16, 21-23 after treatment. The cure rate with 300 mg mebendazole was 16.1% with 90.9% egg reduction while 600 mg mebendazole gave 91.4% cure rate with 99.5% egg reduction. No side effects were observed in all children. Four hundred and six adult worms were identified, 99% were Necator Americanus, 0.5% Ancylostoma duodenale and 0.5% Ancylostoma ceylanicum.

Adolescent↗
PubMed1983

Treatment of Brugia malayi infection with mebendazole and levamisole.

Brugia malayi microfilaraemic patients were treated with either mebendazole 500 mg thrice daily for 21 days or a combination of a similar dose of mebendazole with levamisole hydrochloride 2.5 mg/kg weekly for 3 weeks. Although both regimes were effective, the addition of low doses of levamisole to mebendazole hastened the conversion of all patients to amicrofilaraemia, this being achieved by the second post-treatment week. No serious side reaction was encountered in the use of this high dose of mebendazole. Further experimental studies are necessary to determine whether the drug is adulticidal or only embryostatic.

Adolescent↗
PubMed1984

Anthelmintic efficacy of mebendazole suspension against induced helminth infections in South African sheep and cattle.

Critical controlled tests were performed in 157 sheep (8 experiments) and 34 cattle (2 experiments) to evaluate the anthelmintic activity of mebendazole suspension, administered intraruminally via a stomach tube at a dosage rate of 15 mg of mebendazole/kg of body weight, against induced infections of immature and adult stages of commonly encountered nematode parasites in South Africa. In the sheep, the controlled efficacy of mebendazole suspension was good to excellent (90.1% to 100%) against all stages of Haemonchus contortus, Trichostrongylus colubriformis, Gaigeria pachyscelis, Ostertagia circumcincta, Nematodirus spathiger, and Chabertia ovina species. Mebendazole was also highly effective (97.3% to 99.9%) against 4th, 5th, and adult stages of Oesophagostomum columbianum and 5th-stage and adult Dictyocaulus filaria. Moderate activity was obtained (79.8% to 82.2%) against 3rd-stage O columbianum, 3rd- and 4th-stage D filaria, and 5th-stage and adult Strongyloides papillosus. In the cattle, mebendazole was effective (91.5% to 100%) against 4th-stage and adult H placei, Cooperia pectinata, Bunostomum phlebotomum, and Oesophagostomum radiatum species, but did not exhibit any appreciable activity (27.3% to 41.5%) against 4th-stage and adult O ostertagi.

Administration, Oral↗
PubMed1982

Treatment of human echinococcosis with mebendazole. Preliminary observations in 28 patients.

Preliminary results of a long-term, prospective therapeutic trial with mebendazole in 28 patients mainly with inoperable echinococcosis are reported. The course of disease was monitored closely and plasma mebendazole levels were checked regularly. A major problem is the lack of reliable methods for defining and measuring early success or failure of therapy. Most of the patients improved clinically. No marked change of parasitic lesions was observed except in one patient with constantly low plasma mebendazole levels who deteriorated. No serious side effects occurred. The preliminary results are encouraging and suggest that mebendazole has a "parasitostatic" effect on larval growth.

Adult↗
PubMed1983

Mebendazole concentrations in sheep plasma.

Formulated mebendazole was administered to sheep by intraruminal injection at dose rates of 12.5, 25, 50 or 100 mg/kg bodyweight. The concentrations of mebendazole and two major metabolites were measured by high-performance liquid chromatography in plasma taken at intervals up to 48 hours after treatment. At 12.5 mg/kg the peak plasma concentration was 0.22 +/- 0.03 microM mebendazole, rising to 0.76 +/- 0.04 microM at 100 mg/kg. Peak plasma concentrations occurred between nine and 24 hours for all dose rates and declined rapidly. Two major metabolites were detected; their concentrations exceeded that of mebendazole at all dose rates.

Animals↗